Stock Events

Eisai 

€9.3
38
+€0+0% Today

Statistics

Day High
9.3
Day Low
9.25
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
2.53%
Dividend
0.23

Upcoming

Dividends

2.53%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-8.59%

Earnings

15MayConfirmed
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.06
0.27
0.48
0.68
Expected EPS
0.24438311918045216
Actual EPS
0.24271700587705486

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EIIA.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Show more...
CEO
Mr. Haruo Naito
Employees
11067
Country
JP
ISIN
US28258A1079
WKN
000A3D5BP

Listings